-

REPORT

Milliman Study on the Utility of ICER Reports for Private Payer Drug Coverage Decision-Making

To download the full report, click here.

A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be very useful for private payers’ medicine coverage decisions. The whitepaper identifies several problems in applying ICER’s reports to inform coverage decisions by private payers